GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CStone Pharmaceuticals (HKSE:02616) » Definitions » Asset Turnover

CStone Pharmaceuticals (HKSE:02616) Asset Turnover : 0.16 (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is CStone Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. CStone Pharmaceuticals's Revenue for the six months ended in Jun. 2023 was HK$286.0 Mil. CStone Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was HK$1,829.7 Mil. Therefore, CStone Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2023 was 0.16.

Asset Turnover is linked to ROE % through Du Pont Formula. CStone Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2023 was -91.22%. It is also linked to ROA % through Du Pont Formula. CStone Pharmaceuticals's annualized ROA % for the quarter that ended in Jun. 2023 was -25.02%.


CStone Pharmaceuticals Asset Turnover Historical Data

The historical data trend for CStone Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CStone Pharmaceuticals Asset Turnover Chart

CStone Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - 0.32 0.08 0.23 0.28

CStone Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.12 0.12 0.16 -

Competitive Comparison of CStone Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, CStone Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CStone Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CStone Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where CStone Pharmaceuticals's Asset Turnover falls into.



CStone Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

CStone Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=507.341/( (1829.656+1817.859)/ 2 )
=507.341/1823.7575
=0.28

CStone Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Jun. 2023 ))/ count )
=285.995/( (1829.656+0)/ 1 )
=285.995/1829.656
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


CStone Pharmaceuticals  (HKSE:02616) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

CStone Pharmaceuticals's annulized ROE % for the quarter that ended in Jun. 2023 is

ROE %**(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-457.694/501.769
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-457.694 / 571.99)*(571.99 / 1829.656)*(1829.656/ 501.769)
=Net Margin %*Asset Turnover*Equity Multiplier
=-80.02 %*0.3126*3.6464
=ROA %*Equity Multiplier
=-25.02 %*3.6464
=-91.22 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

CStone Pharmaceuticals's annulized ROA % for the quarter that ended in Jun. 2023 is

ROA %(Q: Jun. 2023 )
=Net Income/Total Assets
=-457.694/1829.656
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-457.694 / 571.99)*(571.99 / 1829.656)
=Net Margin %*Asset Turnover
=-80.02 %*0.3126
=-25.02 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


CStone Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of CStone Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


CStone Pharmaceuticals (HKSE:02616) Business Description

Traded in Other Exchanges
Address
218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Shanghai, CHN, 215123
CStone Pharmaceuticals is engaged in the development and commercialization of innovative tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.

CStone Pharmaceuticals (HKSE:02616) Headlines

No Headlines